請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72534
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 朱清良(Ching-Liang Chu) | |
dc.contributor.author | Jung-Chien Ma | en |
dc.contributor.author | 馬榮謙 | zh_TW |
dc.date.accessioned | 2021-06-17T07:00:28Z | - |
dc.date.available | 2024-08-27 | |
dc.date.copyright | 2019-08-27 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-08-02 | |
dc.identifier.citation | 1. Bader HL, Hsu T. Systemic VHL gene functions and the VHL disease. FEBS Lett. 2012;586(11):1562-9.
2. Kaelin WG. Von Hippel-Lindau disease. Annu Rev Pathol. 2007;2:145-73. 3. Walmsley SR, McGovern NN, Whyte MK, Chilvers ER. The HIF/VHL pathway: from oxygen sensing to innate immunity. Am J Respir Cell Mol Biol. 2008;38(3):251-5. 4. Eltzschig HK, Bratton DL, Colgan SP. Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases. Nat Rev Drug Discov. 2014;13(11):852-69. 5. Tabaro F, Minervini G, Sundus F, Quaglia F, Leonardi E, Piovesan D, et al. VHLdb: A database of von Hippel-Lindau protein interactors and mutations. Sci Rep. 2016;6:31128. 6. Hsu T. Complex cellular functions of the von Hippel-Lindau tumor suppressor gene: insights from model organisms. Oncogene. 2012;31(18):2247-57. 7. Cramer T, Yamanishi Y, Clausen BE, Forster I, Pawlinski R, Mackman N, et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell. 2003;112(5):645-57. 8. Doedens AL, Phan AT, Stradner MH, Fujimoto JK, Nguyen JV, Yang E, et al. Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen. Nat Immunol. 2013;14(11):1173-82. 9. Lee JH, Elly C, Park Y, Liu YC. E3 Ubiquitin Ligase VHL Regulates Hypoxia-Inducible Factor-1alpha to Maintain Regulatory T Cell Stability and Suppressive Capacity. Immunity. 2015;42(6):1062-74. 10. Li Q, Li D, Zhang X, Wan Q, Zhang W, Zheng M, et al. E3 Ligase VHL Promotes Group 2 Innate Lymphoid Cell Maturation and Function via Glycolysis Inhibition and Induction of Interleukin-33 Receptor. Immunity. 2018;48(2):258-70 e5. 11. Italiani P, Boraschi D. From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation. Front Immunol. 2014;5:514. 12. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14-20. 13. Lawrence T. The Nuclear Factor NF-κB Pathway in Inflammation. Cold Spring Harbor Perspectives in Biology. 2009;1(6). 14. Roszer T. Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms. Mediators Inflamm. 2015;2015:816460. 15. Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(9):5336-41. 16. Ertel W, Morrison MH, Ayala A, Chaudry IH. Hypoxemia in the absence of blood loss or significant hypotension causes inflammatory cytokine release. The American journal of physiology. 1995;269(1 Pt 2):R160-6. 17. Roe JS, Kim H, Lee SM, Kim ST, Cho EJ, Youn HD. p53 stabilization and transactivation by a von Hippel-Lindau protein. Molecular cell. 2006;22(3):395-405. 18. Semenza GL. VHL and p53: tumor suppressors team up to prevent cancer. Molecular cell. 2006;22(4):437-9. 19. Li L, Ng DS, Mah WC, Almeida FF, Rahmat SA, Rao VK, et al. A unique role for p53 in the regulation of M2 macrophage polarization. Cell death and differentiation. 2015;22(7):1081-93. 20. Choe SS, Shin KC, Ka S, Lee YK, Chun JS, Kim JB. Macrophage HIF-2alpha ameliorates adipose tissue inflammation and insulin resistance in obesity. Diabetes. 2014;63(10):3359-71. 21. Fujisaka S, Usui I, Ikutani M, Aminuddin A, Takikawa A, Tsuneyama K, et al. Adipose tissue hypoxia induces inflammatory M1 polarity of macrophages in an HIF-1alpha-dependent and HIF-1alpha-independent manner in obese mice. Diabetologia. 2013;56(6):1403-12. 22. Lin N, Simon MC. Hypoxia-inducible factors: key regulators of myeloid cells during inflammation. J Clin Invest. 2016;126(10):3661-71. 23. Guo Y, Schoell MC, Freeman RS. The von Hippel-Lindau protein sensitizes renal carcinoma cells to apoptotic stimuli through stabilization of BIM(EL). Oncogene. 2009;28(16):1864-74. 24. Hsu T, Adereth Y, Kose N, Dammai V. Endocytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motility. J Biol Chem. 2006;281(17):12069-80. 25. Yang H, Minamishima YA, Yan Q, Schlisio S, Ebert BL, Zhang X, et al. pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Molecular cell. 2007;28(1):15-27. 26. Danilin S, Sourbier C, Thomas L, Rothhut S, Lindner V, Helwig JJ, et al. von Hippel-Lindau tumor suppressor gene-dependent mRNA stabilization of the survival factor parathyroid hormone-related protein in human renal cell carcinoma by the RNA-binding protein HuR. Carcinogenesis. 2009;30(3):387-96. 27. Kantari-Mimoun C, Krzywinska E, Castells M, Milien C, Klose R, Meinecke AK, et al. Boosting the hypoxic response in myeloid cells accelerates resolution of fibrosis and regeneration of the liver in mice. Oncotarget. 2017;8(9):15085-100. 28. Kobayashi H, Gilbert V, Liu Q, Kapitsinou PP, Unger TL, Rha J, et al. Myeloid cell-derived hypoxia-inducible factor attenuates inflammation in unilateral ureteral obstruction-induced kidney injury. J Immunol. 2012;188(10):5106-15. 29. Keranen MAI, Raissadati A, Nykanen AI, Dashkevich A, Tuuminen R, Krebs R, et al. Hypoxia-inducible factor controls immunoregulatory properties of myeloid cells in mouse cardiac allografts - an experimental study. Transpl Int. 2019;32(1):95-106. 30. Arango Duque G, Descoteaux A. Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol. 2014;5:491. 31. Veremeyko T, Yung AWY, Anthony DC, Strekalova T, Ponomarev ED. Early Growth Response Gene-2 Is Essential for M1 and M2 Macrophage Activation and Plasticity by Modulation of the Transcription Factor CEBPbeta. Front Immunol. 2018;9:2515. 32. Odkhuu E, Mendjargal A, Koide N, Naiki Y, Komatsu T, Yokochi T. Lipopolysaccharide downregulates the expression of p53 through activation of MDM2 and enhances activation of nuclear factor-kappa B. Immunobiology. 2015;220(1):136-41. 33. Liu G, Park YJ, Tsuruta Y, Lorne E, Abraham E. p53 Attenuates lipopolysaccharide-induced NF-kappaB activation and acute lung injury. J Immunol. 2009;182(8):5063-71. 34. Zheng SJ, Lamhamedi-Cherradi SE, Wang P, Xu L, Chen YH. Tumor suppressor p53 inhibits autoimmune inflammation and macrophage function. Diabetes. 2005;54(5):1423-8. 35. Zhang X, He X, Liu C, Liu J, Hu Q, Pan T, et al. IL-4 Inhibits the Biogenesis of an Epigenetically Suppressive PIWI-Interacting RNA To Upregulate CD1a Molecules on Monocytes/Dendritic Cells. J Immunol. 2016;196(4):1591-603. 36. Lagasse HA, Alexaki A, Simhadri VL, Katagiri NH, Jankowski W, Sauna ZE, et al. Recent advances in (therapeutic protein) drug development. F1000Res. 2017;6:113. 37. Uribe-Echeverry PT, Lopez-Gartner GA. Fungal immunomodulatory proteins in the context of biomedicine. Front Biosci (Elite Ed). 2017;9:286-306. 38. Kino K, Yamashita A, Yamaoka K, Watanabe J, Tanaka S, Ko K, et al. Isolation and characterization of a new immunomodulatory protein, ling zhi-8 (LZ-8), from Ganoderma lucidium. Journal of Biological Chemistry. 1989;264(1):472-8. 39. Tanaka S, Ko K, Kino K, Tsuchiya K, Yamashita A, Murasugi A, et al. Complete amino acid sequence of an immunomodulatory protein, ling zhi-8 (LZ-8). An immunomodulator from a fungus, Ganoderma lucidium, having similarity to immunoglobulin variable regions. Journal of Biological Chemistry. 1989;264(28):16372-7. 40. Ko JL, Lin SJ, Hsu CI, Kao CL, Lin JY. Molecular cloning and expression of a fungal immunomodulatory protein, FIP-fve, from Flammulina velutipes. J Formos Med Assoc. 1997;96(7):517-24. 41. Rosano GL, Ceccarelli EA. Recombinant protein expression in Escherichia coli: advances and challenges. Frontiers in microbiology. 2014;5:172. 42. Lin JW, Jia J, Shen YH, Zhong M, Chen LJ, Li HG, et al. Functional expression of FIP-fve, a fungal immunomodulatory protein from the edible mushroom Flammulina velutipes in Pichia pastoris GS115. J Biotechnol. 2013;168(4):527-33. 43. Qu ZW, Zhou SY, Guan SX, Gao R, Duan ZW, Zhang X, et al. Recombinant Expression and Bioactivity Comparison of Four Typical Fungal Immunomodulatory Proteins from Three Main Ganoderma Species. BMC Biotechnol. 2018;18(1):80. 44. Min B. Spontaneous T Cell Proliferation: A Physiologic Process to Create and Maintain Homeostatic Balance and Diversity of the Immune System. Frontiers in immunology. 2018;9:547. 45. Ko JL, Hsu CI, Lin RH, Kao CL, Lin JY. A new fungal immunomodulatory protein, FIP‐fve isolated from the edible mushroom, Flammulina velutipes and its complete amino acid sequence. European Journal of Biochemistry. 1995;228(2):244-9. 46. Spangler JB, Moraga I, Mendoza JL, Garcia KC. Insights into cytokine-receptor interactions from cytokine engineering. Annu Rev Immunol. 2015;33:139-67. 47. Haak-Frendscho M, Kino K, Sone T, Jardieu P. Ling Zhi-8: a novel T cell mitogen induces cytokine production and upregulation of ICAM-1 expression. Cellular immunology. 1993;150(1):101-13. 48. Yeh CM, Yeh CK, Hsu XY, Luo QM, Lin MY. Extracellular expression of a functional recombinant Ganoderma lucidium immunomodulatory protein by Bacillus subtilis and Lactococcus lactis. Appl Environ Microbiol. 2008;74(4):1039-49. 49. Licona-Limon P, Kim LK, Palm NW, Flavell RA. TH2, allergy and group 2 innate lymphoid cells. Nat Immunol. 2013;14(6):536-42. 50. Sampath V, Nadeau KC. Newly identified T cell subsets in mechanistic studies of food immunotherapy. J Clin Invest. 2019;129(4):1431-40. 51. Jeurink PV, Noguera CL, Savelkoul HF, Wichers HJ. Immunomodulatory capacity of fungal proteins on the cytokine production of human peripheral blood mononuclear cells. Int Immunopharmacol. 2008;8(8):1124-33. 52. Wu CT, Lin TY, Hsu HY, Sheu F, Ho CM, Chen EI. Ling Zhi-8 mediates p53-dependent growth arrest of lung cancer cells proliferation via the ribosomal protein S7-MDM2-p53 pathway. Carcinogenesis. 2011;32(12):1890-6. 53. Liao CH, Hsiao YM, Lin CH, Yeh CS, Wang JC, Ni CH, et al. Induction of premature senescence in human lung cancer by fungal immunomodulatory protein from Ganoderma tsugae. Food Chem Toxicol. 2008;46(5):1851-9. 54. Lin C-H, Sheu G-T, Lin Y-W, Yeh C-S, Huang Y-H, Lai Y-C, et al. A new immunomodulatory protein from Ganoderma microsporum inhibits epidermal growth factor mediated migration and invasion in A549 lung cancer cells. Process Biochemistry. 2010;45(9):1537-42. 55. Lin CC, Yu YL, Shih CC, Liu KJ, Ou KL, Hong LZ, et al. A novel adjuvant Ling Zhi-8 enhances the efficacy of DNA cancer vaccine by activating dendritic cells. Cancer Immunol Immunother. 2011;60(7):1019-27. 56. Ding Y, Seow SV, Huang CH, Liew LM, Lim YC, Kuo IC, et al. Coadministration of the fungal immunomodulatory protein FIP-Fve and a tumour-associated antigen enhanced antitumour immunity. Immunology. 2009;128(1 Suppl):e881-94. 57. Hao-Chi H, Chyong-Ing H, Rong-Hwa L, Chian-Liang K, Jung-Yaw L. Fip-vvo, a new fungal immunomodulatory protein isolated from Volvariella volvacea. Biochemical Journal. 1997;323(2):557-65. 58. Bao D, Wang H. Identification and Application of Volvariella volvacea Mating Type Genes to Mushroom Breeding. Mushroom Biotechnology2016. p. 191-201. 59. Cheung PCK. The nutritional and health benefits of mushrooms. Nutrition Bulletin. 2010;35(4):292-9. 60. Wang X-f, Su K-q, Bao T-w, Cong W-r, Chen Y-f, Li Q-z, et al. Immunomodulatory effects of fungal proteins. Current Topics in Nutraceuticals Research. 2012;10(1):1. 61. Maiti S, Bhutia SK, Mallick SK, Kumar A, Khadgi N, Maiti TK. Antiproliferative and immunostimulatory protein fraction from edible mushrooms. Environ Toxicol Pharmacol. 2008;26(2):187-91. 62. Sun X, Huang W, Xiao S, Liang C, Zhang S, Liu Z, et al. Extracellular expression and efficient purification of a functional recombinant Volvariella volvacea immunomodulatory protein (FIP-vvo) using Pichia pastoris system. Protein Expr Purif. 2014;94:95-100. 63. Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol. 2012;30:1-22. 64. Dalod M, Chelbi R, Malissen B, Lawrence T. Dendritic cell maturation: functional specialization through signaling specificity and transcriptional programming. Embo j. 2014;33(10):1104-16. 65. Pulendran B. The varieties of immunological experience: of pathogens, stress, and dendritic cells. Annu Rev Immunol. 2015;33:563-606. 66. Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nature Reviews Immunology. 2003;3:984. 67. Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nature reviews Immunology. 2007;7(10):790-802. 68. Lin YL, Liang YC, Tseng YS, Huang HY, Chou SY, Hseu RS, et al. An immunomodulatory protein, Ling Zhi-8, induced activation and maturation of human monocyte-derived dendritic cells by the NF-kappaB and MAPK pathways. J Leukoc Biol. 2009;86(4):877-89. 69. Hubbell JA, Thomas SN, Swartz MA. Materials engineering for immunomodulation. Nature. 2009;462(7272):449-60. 70. Petrovsky N. Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs. Drug safety. 2015;38(11):1059-74. 71. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nature reviews Immunology. 2002;2(4):251-62. 72. Saeki H, Moore AM, Brown MJ, Hwang ST. Cutting edge: secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes. Journal of immunology (Baltimore, Md : 1950). 1999;162(5):2472-5. 73. Awate S, Babiuk LA, Mutwiri G. Mechanisms of action of adjuvants. Frontiers in immunology. 2013;4:114. 74. Montoya M, Schiavoni G, Mattei F, Gresser I, Belardelli F, Borrow P, et al. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood. 2002;99(9):3263-71. 75. Huang RY, Yu YL, Cheng WC, OuYang CN, Fu E, Chu CL. Immunosuppressive effect of quercetin on dendritic cell activation and function. Journal of immunology (Baltimore, Md : 1950). 2010;184(12):6815-21. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72534 | - |
dc.description.abstract | 第一章
巨噬細胞是先天免疫中重要的防禦角色,除了主導生理上之發炎反應,經不同刺激可以將巨噬細胞極化為M1和M2兩類族群,分別促進發炎及調控組織修復。過去對巨噬細胞在發炎反應的研究已趨於成熟,但是對巨噬細胞極化成M1和M2的相關機制仍不完整。Von Hippel-Lindau (VHL)基因是一抑制腫瘤基因,該基因的突變在人體會造成一系列之腫瘤的發生。VHL基因所編碼的蛋白為一E3泛素連接酶,對於調控蛋白的分解為一重要的角色。VHL的影響相當廣泛,例如會辨識低氧誘發因子-1α (HIF-1α)並調控細胞面對低氧環境的反應。過去研究已知Vhl基因剔除的巨噬細胞在小鼠發炎模式下有更強的發炎反應,但VHL調控巨噬細胞的極化現象仍不清楚,因此本研究主要針對VHL調控巨噬細胞的極化進行探討。在本研究中我們經siRNA轉染以降低小鼠骨髓分化巨噬細胞中Vhl基因及蛋白的表現,且在此系統下比較巨噬細胞極化現象,發現降低Vhl表現之巨噬細胞在M1有較低之Tnfa、Il1b的基因表現,而在M2則有較高之Arg1、Ym1、Fizz1的基因表現。而經流式細胞術分析可發現降低Vhl表現之巨噬細胞在M1有較低之MHCII、CD86的表現,而在M2則有較高之PD-L2表現。為探討Vhl調控巨噬細胞極化的機制,根據過去研究我們探討Vhl、Hif1α、p53之間的調控,卻發現在我們培養之骨髓分化巨噬細胞的p53蛋白表現與過去研究相互矛盾,故降低Vhl表現之巨噬細胞比較p53、Hif1α、HIF2α的基因表現,結果並無觀察到顯著差異。在本研究中我們發現降低Vhl表現之巨噬細胞有相對較低之M1極化能力與相對較高之M2極化能力,但其機制與功能性探討仍須被探討和驗證。 第二章 真菌免疫調節蛋白為一群具有相似胺基酸序列、結構與免疫調節功能的真菌蛋白。過去研究顯示真菌免疫調節蛋白可促使免疫細胞增殖、分泌細胞激素,和抑制過敏及腫瘤。真菌免疫調節蛋白的物種來源多樣性,使不同來源的真菌免疫調節蛋白之特性仍待驗證。樹突細胞為主要負責抗原呈現及調控發炎反應的免疫細胞。樹突細胞在接觸抗原後會活化並將抗原呈現給輔助型T細胞以啟動後天免疫反應,故樹突細胞在調節免疫中為一重要的角色。過去研究指出真菌免疫調節蛋白如LZ-8、FIP-Fve可以活化樹突細胞,並且可作為疫苗之佐劑增強疫苗的功效。不過真菌免疫調節蛋白中的草菇免疫調節蛋白 (FIP-Vvo) 在樹突細胞的影響仍未被探討。本研究遂利用Saccharomyces cerevisiae生產之重組FIP-Vvo在小鼠骨髓分化樹突細胞上之影響進行探討。我們發現經FIP-Vvo刺激可促使骨髓分化樹突細胞之第二型主要組織相容性複合體表現增加,且可促進其分泌促發炎激素-介白素-6、介白素-12,與可活化T細胞之介白素-2。最後FIP-Vvo可增強骨髓分化樹突細胞促使抗原專一性的CD4+ T細胞增生之能力。本研究顯示S. cerevisiae生產之重組FIP-Vvo可部分活化小鼠骨髓分化樹突細胞,卻可增加其活化抗原專一性的CD4+ T細胞增生的功能,使重組FIP-Vvo可成為疫苗佐劑的一潛在目標。 | zh_TW |
dc.description.abstract | Chapter 1
Macrophages play a crucial role in killing pathogens and regulating the inflammatory response in innate immunity. Depending on different stimuli and cytokines in microenvironment, macrophages can polarize towards two opposite functional states M1 and M2 types. In this study we explore the role of Von Hippel-Lindau (VHL) in macrophage polarization. Vhl gene is a tumor suppressor gene. Moreover, inheritance of a mutated Vhl gene in human causes VHL disease, an autosomal-dominant cancer syndrome. VHL gene encodes a E3 ubiquitin ligase which serves as a chaperon and promotes protein degradation. Previous study has shown that macrophage-specific Vhl-/- possessed stronger inflammatory ability. However, the role of VHL in M2 macrophage polarization remains unknown. In our study, we found that knockdown Vhl in bone marrow-derived macrophages (BMDM) by siRNA transfection could suppress Tnfa and Il1b mRNA expression in M1 subset. Furthermore, it could promote Arg1, Ym1 and Fizz1 mRNA expression in M2 subset. Moreover, by flow cytometry analysis, we found that knockdown Vhl in BMDM had lower MHCII and CD86 expression in M1 cells, whereas it had higher PD-L2 expression in M2 cells. To study the mechanism mediated by VHL in macrophage polarization, we focus on the expression of Hif1α and p53, both of which have been reported to interact with Vhl and have impact on macrophage polarization. However, our result of p53 expression in macrophage polarization was contradictory to previous study. Then we examined p53, Hif1α and Hif2α mRNA expression, and found that no significant difference between knockdown Vhl and control macrophages. In our study, we found that knockdown Vhl in BMDM suppress the capability of M1 polarization, whereas enhance the capability of M2 polarization. Nevertheless, the mechanism and functional test of polarization need to be further studied. Chapter 2 Fungal immunomodulatory protein (FIP) is a group of proteins isolated from fungi, and which has similar amino acid sequence and immune modulatory capability. Previous studies indicated that FIPs could promote proliferation and cytokine production of immune cells. FIPs have been shown to have the immunomodulatory effect on allergy and immunotherapy to tumor. Dendritic cell is the most potent antigen-presenting cell. Furthermore, induction of mature dendritic cell is critical for directing immune response, including inflammation and adaptive immunity. Previous studies have shown that LZ-8 and FIP-Fve, the typical members in FIP family, activate dendritic cell, and may be a potential adjuvant to enhance the efficacy of vaccine. However, the immunomodulatory effect of FIP-Vvo, the FIP from Volvariella volvacea, on dendritic cell remain unknown. Here, we employ mouse bone marrow-derived dendritic cell (BMDC) to investigate the immunomodulatory effect of the recombinant FIP-Vvo, which is produced by cloned Saccharomyces cerevisiae expression system. We found that treatment of BMDC with recombinant FIP-Vvo could induce the expression of MHC II, as well as the production of IL-2 and IL-6. Furthermore, recombinant FIP-Vvo enhanced the ability of BMDC to induce antigen specific CD4 T cell proliferation. These results suggest that the recombinant FIP-Vvo is able to partially activate BMDC. Furthermore, it can increase the ability of BMDC to induce antigen the proliferation of specific CD4 T cell. Thus, recombinant FIP-Vvo could be a potential adjuvant for vaccination. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T07:00:28Z (GMT). No. of bitstreams: 1 ntu-108-R06449011-1.pdf: 3449575 bytes, checksum: 718883d0969ed9609974bc175018d4e7 (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 口試委員會審定書 i
致謝 ii 中文摘要 iii 第一章 iii 第二章 iv Abstract v Chapter 1 v Chapter 2 vii 目錄 ix 圖目錄 xiii 第一章 1 一、 背景介紹 (Introduction) 2 1. Von Hippel-Lindau(VHL) 2 2. VHL之相關研究 3 3. 巨噬細胞(Macrophage) 3 3.1. 巨噬細胞極化-M1細胞 4 3.2. 巨噬細胞極化-M2細胞 4 二、 研究動機 (Rationale) 6 三、 研究目標 (Specific Aims) 6 1. 實驗小鼠與材料 7 2. 骨髓分化巨噬細胞之培養與極化Generation and polarization of bone marrow-derived macrophages (BMDMs) 7 3. 以小分子干擾核糖核酸 (small interfering RNA, siRNA) 轉染骨髓分化巨噬細胞BMDM knockdown by siRNA transfection 8 4. 核糖核酸萃取 (RNA extraction) 與核酸序列定量偵測系統 (Quantitative polymerase chain reaction, qPCR) 8 5. 細胞表面分子染色與流式細胞術分析 (Flow cytometry system, FCS) 8 6. 細胞蛋白萃取、電泳 (Electrophoresis) 與西方墨點法 (Western blot) 9 7. 統計分析 10 五、 實驗結果(Results) 11 1. 建立以Vhl siRNA轉染來降低小鼠骨髓分化巨噬細胞 (BMDM) 中Vhl基因表現之系統 11 2. Knockdown Vhl之骨髓分化巨噬細胞對極化上的基因表現量影響 12 3. Knockdown Vhl之骨髓分化巨噬細胞對極化上的細胞表面標記表現量影響 12 4. Vhl調控之HIF-1α、p53在骨髓分化巨噬細胞極化的表現變化 13 5. Knockdown Vhl之骨髓分化巨噬細胞的p53、Hif-1α、Hif-2α基因表現 13 六、 討論 (Discussion) 15 七、 附圖 (Figures) 19 第二章 30 一、 背景介紹 (Introduction) 31 1. Fungal immunomodulatory protein of Volvariella volvacea (FIP-Vvo) 31 1.1. 發展及生產Fungal immunomodulatory proteins (FIPs) 31 1.2. FIPs的生物活性 32 1.2.1. 紅血球凝集 32 1.2.2. 促有絲分裂 32 1.2.3. 細胞激素分泌 33 1.2.4. 抗過敏與抑制腫瘤反應 33 1.3. FIP-Vvo 34 2. 樹突細胞 (Dendritic cell, DC) 35 3. FIPs在樹突細胞之研究應用 35 二、 研究動機 (Rationale) 37 三、 研究目標 (Specific Aims) 37 四、 實驗材料與方法 (Materials and methods) 38 1. 實驗小鼠與材料 38 2. 骨髓分化樹突細胞之培養Generation of bone marrow-derived dendritic cells (BMDCs) 38 3. 骨髓分化樹突細胞之成熟與LZ-8、FIP-Vvo刺激 38 4. Fip-Vvo細胞毒性測試Fip-Vvo cytotoxicity assay 39 5. 核糖核酸萃取 (RNA extraction) 與核酸序列定量偵測系統 (Quantitative polymerase chain reaction, qPCR) 39 6. 細胞表面分子染色與流式細胞術分析 (Flow cytometry system, FCS) 39 7. 細胞內染(intracellular staining) TNF-α 40 8. 酵素免疫分析法 (Enzyme-linked immunosorbent assay, ELISA) 40 9. 骨髓分化樹突細胞與T細胞共培養實驗 41 10. 統計分析 42 五、 實驗結果 (Results) 43 1. 培養小鼠骨髓分化樹突細胞與測試FIP-Vvo對該培養之細胞毒性 43 2. 分析小鼠骨髓分化樹突細胞在FIP-Vvo刺激下的成熟反應 43 3. 分析小鼠骨髓分化樹突細胞在FIP-Vvo刺激下對細胞激素分泌的影響 44 4. 分析小鼠骨髓分化樹突細胞在FIP-Vvo刺激下對CD4+ T細胞增生的影響 44 六、 討論 (Discussion) 46 七、 附圖 (Figures) 49 參考資料 (References) 56 | |
dc.language.iso | zh-TW | |
dc.title | 探討Vhl在巨噬細胞中調控細胞極化之角色 | zh_TW |
dc.title | The role of Vhl (von Hippel–Lindau tumor suppressor)
in the polarization of macrophage | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 徐立中(Li-Chung Hsu),繆希椿(Shi-Chuen Miaw) | |
dc.subject.keyword | Von Hippel-Lindau,巨噬細胞,極化,低氧誘發因子-1α,低氧誘發因子-2α,p53,真菌免疫調節蛋白,Volvariella volvacea,樹突細胞,成熟, | zh_TW |
dc.subject.keyword | Von Hippel-Lindau,macrophage,polarization,Hypoxia induce factor -1α,Hypoxia induce factor -2α,p53,Fungal immunomodulatory protein,Volvariella volvacea,dendritic cell,maturation, | en |
dc.relation.page | 64 | |
dc.identifier.doi | 10.6342/NTU201902441 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-08-02 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 免疫學研究所 | zh_TW |
顯示於系所單位: | 免疫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 3.37 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。